Apricus Biosciences Inc. (NASDAQ:APRI) – Investment analysts at Roth Capital boosted their FY2016 earnings per share (EPS) estimates for Apricus Biosciences in a research note issued on Thursday. Roth Capital analyst S. Henry now expects that the brokerage will earn ($1.40) per share for the year, up from their previous forecast of ($1.80). Roth Capital also issued estimates for Apricus Biosciences’ Q4 2016 earnings at ($0.24) EPS and FY2017 earnings at ($0.25) EPS.

Separately, Zacks Investment Research raised Apricus Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 18th.

Earnings History and Estimates for Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences (NASDAQ:APRI) opened at 1.56 on Monday. Apricus Biosciences has a 52-week low of $1.48 and a 52-week high of $15.50. The company’s 50-day moving average price is $1.32 and its 200 day moving average price is $0.62. The firm’s market capitalization is $12.06 million.

Apricus Biosciences (NASDAQ:APRI) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.41. The company had revenue of $4.30 million for the quarter, compared to analyst estimates of $1.91 million. During the same period last year, the firm posted ($1.00) earnings per share.

An institutional investor recently raised its position in Apricus Biosciences stock. Vanguard Group Inc. boosted its stake in shares of Apricus Biosciences Inc. (NASDAQ:APRI) by 0.7% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,511,841 shares of the company’s stock after buying an additional 9,786 shares during the period. Vanguard Group Inc. owned 2.44% of Apricus Biosciences worth $604,000 at the end of the most recent quarter.

COPYRIGHT VIOLATION WARNING: “FY2016 EPS Estimates for Apricus Biosciences Inc. Boosted by Roth Capital (APRI)” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2016/11/23/fy2016-eps-estimates-for-apricus-biosciences-inc-boosted-by-roth-capital-apri.html.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

5 Day Chart for NASDAQ:APRI

Receive News & Stock Ratings for Apricus Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc. and related stocks with our FREE daily email newsletter.